| Date | Title | Description |
| 16.08.2024 | A New Dawn in Cancer Research: AI and Funding Unite for Hope | In the battle against cancer, innovation is the sword and funding is the shield. Two recent developments highlight this truth: a groundbreaking collaboration between Absci Corporation and Memorial Sloan Kettering Cancer Center (MSK), and a ... |
| 12.08.2024 | Absci and MSK Collaborate on Generative AI Drug Discovery | What You Should Know:
– Absci Corporation, a leader in generative AI drug creation, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop up to six novel cancer therapeutics.
– By combining A... |
| 20.05.2024 | SynBioBeta 2024: From novel hosts to ‘tricking’ cells to be more productive… addressing the ‘scale-cost paradox’ in biomanufacturing | Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidl... |
| 02.04.2024 | Экономический анализ: как генеративный ИИ меняет производительность труда и перспективы профессий | На связи Алексей Мартынов и Денис Ларионов, мы продолжаем делиться актуальной аналитикой о генеративном ИИ. Предыдущую нашу статью с описанием текущего положения дел на рынке генеративного ИИ и прогнозом до 2032 года найдёте здесь .
Для тех... |
| 06.03.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| 28.02.2024 | Absci Announces $75M Public Offering to Fuel AI Drug Creation | What You Should Know:
– Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock.
– This IPO aims to support the advancement of A... |
| 20.12.2023 | Absci, PrecisionLife Partner to Develop AI-Enabled Drug Pipeline | What You Should Know:
– Absci, a generative AI drug creation company, and PrecisionLife, a pioneer in computational biology for complex chronic diseases, have announced a powerful partnership to develop a joint portfolio of potential therap... |
| 04.12.2023 | Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer | What You Should Know:
– Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.
– ... |
| 10.07.2023 | How AI is changing the way scientists engineer drugs, biosensors, enzymes and more | RF Diffusion, a deep learning tool, was prompted to generate a new protein (orange) that binds to the insulin receptor (blue). The tool is now being used by biopharma companies to help design proteins for a variety of uses. Click here for v... |
| 30.06.2023 | Recent Digital Health Hires & Board Appointments | Theralink Technologies, Inc. appoints Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 202... |
| 28.02.2023 | Absci Takes Its Generative AI Antibody Design Platform To Europe | Christine Lemke, SVP of Portfolio & Growth Strategy, Andreas Busch, Chief Innovation Officer, and ... [+] Christian Stegmann, SVP of Drug Creation at Absci.Absci |
| 10.02.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 10th Feb 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 09.02.2023 | Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation | In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in biologic drug creation.
Absci Corporation, ... |
| 10.01.2023 | How generative AI and E. coli are speeding up new drug discovery | Check out all the on-demand sessions from the Intelligent Security Summit here.
For many, hearing the word E. coli is often a reason to be concerned, as the bacteria can lead to incidents of food poisoning in humans.
As it turns out, E. col... |
| 10.01.2023 | Absci First to Create and Validate De Novo Antibodies with Zero-Shot Generative AI | Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver breakthrough therapeutics at the click of a button, for everyone.
Absci Cor... |
| 10.08.2022 | Absci lays off staff as it looks to reorganize amid stock falloff, bear market | Vancouver, WA-based Absci appeared to be riding high after netting greater amounts of funding and even grabbing a deal with Merck in recent months, but now it appears to be in a state of reorganization as the company is b... |
| 22.07.2021 | How Sean McClain founded Absci at just 22 — and now leads a newly public biotech worth nearly $2B | Absci CEO and founder Sean McClain rings the closing bell on the NASDAQ on Thursday with his team as the Vancouver, Wash.-based biotech company went public. (Absci Photo)
Biotech CEOs tend to have advanced degrees and multiple academic cred... |
| 30.06.2021 | Vancouver, Wash. biotech company Absci files to go public | Absci CEO and founder Sean McClain. (Absci Photo)
Absci, a Vancouver, Wash.-based company developing technologies to accelerate the process of drug discovery, announced today that it plans to go public via an IPO. The company’s platform is ... |
| 14.06.2021 | AbSci Announces Acquisition of Target Discovery Company Totient | |
| 23.03.2021 | AbSci announces completion of $125 million crossover financing to advance AI-powered synthetic biology drug creation platform | - |
| 23.03.2021 | Biotech startup AbSci raises $125M for ‘Protein Printing’ tech; total funding up to $230M | AbSci CEO and founder Sean McClain. (AbSci Photo)
New funding: Vancouver, Wash.-based biotech company AbSci raised $125 million in a round led by Casdin Capital and Redmile Group.
The tech: Founded in 2011, AbSci’s “Protein Printing” techno... |
| 23.03.2021 | AbSci Announces Completion of $125 Million Crossover Financing to Advance AI-Powered Synthetic Biology Drug Creation Platform | |
| 05.03.2021 | Biotech startup AbSci lands investment from Merck’s VC arm to fuel ‘Protein Printing’ technology | Vancouver, Wash.-based biotech company AbSci raised an undisclosed amount of funding from pharmaceutical giant Merck.
Founded in 2011, AbSci’s “Protein Printing” technology is used to discover and manufacture complex biological molecules su... |
| 24.02.2021 | AbSci Receives Strategic Investment From Merck Global Health Innovation Fund | AbSci, a Vancouver, Wash.-based synthetic biology company that unifies biologic drug discovery and development processes, received a strategic equity investment from Merck Global Health Innovation Fund (Merck GHI).
The amount of the deal wa... |
| 22.02.2021 | AbSci Announces Strategic Investment by Merck Global Health Innovation Fund | |
| 12.01.2021 | AbSci Announces Acquisition of Deep Learning Company Denovium | |
| 12.01.2021 | AbSci acquires AI startup Denovium to boost synthetic biology platform | AbSci CEO and Founder Sean McClain. (AbSci Photo)
AbSci has acquired Denovium, a 6-person bootstrapped startup out of San Diego that uses deep learning to analyze the function and behavior of proteins.
The deal will help bolster AbSci’s syn... |
| 11.11.2020 | AbSci Announces Recent Additions to Board of Directors | |
| 20.10.2020 | Months after striking a deal with Sanofi, AbSci nails its largest fundraise yet to support its protein printing tech | Months after nailing down a $10.4 million Series D and a partnership with French pharma giant Sanofi, AbSci is pulling in its largest fundraise yet — $65 million to advance what it calls its protein printing tech.
The Vancouv... |
| 20.10.2020 | Synthetic biology startup AbSci raises $65M to expand ‘Protein Printing’ tech | AbSci CEO and Founder Sean McClain. (AbSci Photo)
Vancouver, Wash.-based biotech company AbSci raised an additional $65 million to help grow its synthetic biology platform.
The company’s “Protein Printing” technology is used to discover and... |
| 14.01.2020 | Daily funding roundup - January 14th, 2020 | SurvivorNet, Nicoya, Containous and Lemongrass Consulting raised 10M
Spotio: Spotio is a mobile sales management platform for field sales teams. Spotio has raised $4.5 million in Series A funding from Ballast Point Ventures. More here. Read... |
| 14.01.2020 | AbSci Raises $15.4M in Series D Funding | AbSci, a Vancouver, Wash.-based protein printing company, closed a $10.4M Series D financing.
The round was led by KBI Biopharma and JSR Life Sciences with participation from existing investors Phoenix Venture Partners, Oregon Venture Fund,... |
| 13.01.2020 | AbSci secures $15.4M Series D funding to accelerate growth and scale disruptive protein printing technology | AbSci, a biopharma startup and developer of cutting-edge protein production technologies, has closed $10.4M Series D financing for expansion of AbSci facilities and team in order to meet commercial demand for AbSci’s technology. The round w... |
| 13.01.2020 | AbSci closes $15.4 M in Series D funding to accelerate growth and scale | - |
| 20.06.2018 | AbSci aims to tackle the antibody market after raising $12m to scale E. coli-based tech | - |
| 30.05.2018 | Protein Expression Platform Developer AbSci Raises $12M in Series C | AbSci, a Vancouver, Wash.-based developer of biomanufacturing technologies, completed a $12m Series C financing.
The round was led by Asahi Glass Co., with participation from all prior investors Phoenix Venture Partners, Oregon Venture Fund... |
| 30.05.2018 | Biomanufacturing company AbSci raises $12M to scale synthetic biology platform | - |
| 30.05.2018 | AbSci raises oversubscribed $12M Series C to fuel commercialization of its groundbreaking protein expression platform | - |
| 30.05.2018 | Biomanufacturing company AbSci raises $12M to scale synthetic biology platform | AbSci CEO and Founder Sean McClain. (AbSci Photo)
Vancouver, Wash.,-based biotechnology company AbSci has raised a chunk of new money.
The company announced Wednesday that it has just completed an oversubscribed $12 million Series C round o... |
| 30.05.2018 | Vancouver-based AbSci raises $12 million for research product | - |
| 25.04.2016 | AbSci Secures $5.1M in Series A Financing | AbSci, a Portland, Oregon-based provider of soluble microbial protein expression technology, secured $5.1m in Series A financing.
The round was led by Phoenix Venture Partners. In conjunction with the funding, Dr. Zach Jonasson, General Par... |
